AI assistant
REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2012
Nov 9, 2012
29977_dirs_2012-11-09_c3010e66-0d04-41a5-8946-99acee65eb8e.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: REGENERON PHARMACEUTICALS INC (REGN)
CIK: 0000872589
Period of Report: 2012-11-08
Reporting Person: Powchik Peter (SVP Clinical Development & Reg)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2012-11-08 | Common Stock | S | 14244.0 | $138.59 | Disposed | 15890.0 | Direct |
| 2012-11-08 | Common Stock | S | 900.0 | $139.05 | Disposed | 14990.0 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 1532.0 | Indirect |
Footnotes
F1: Represents volume-weighted average price of sales of 14,244 shares of Company stock on November 8, 2012 at prices ranging from $138.47 to $138.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 8, 2012 at each separate price.
F2: Represents volume-weighted average price of sales of 900 shares of Company stock on November 8, 2012 at prices ranging from $139.00 to $139.27. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 8, 2012 at each separate price.